Atypical clinical presentation of mucopolysaccharidosis type II (Hunter syndrome): a case report by Shah, Gauri Shankar et al.
JOURNAL OF MEDICAL
CASE REPORTS
Shah et al. Journal of Medical Case Reports 2010, 4:154
http://www.jmedicalcasereports.com/content/4/1/154
Open Access CASE REPORT
© 2010 Shah et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Case report Atypical clinical presentation of 
mucopolysaccharidosis type II (Hunter syndrome): 
a case report
Gauri Shankar Shah*, Tania Mahal and Subodh Sharma
Abstract
Introduction: We present a very rare case of mucopolysaccharidosis with atypical presentation such as mild mental 
retardation, an acrocephalic head and no corneal clouding. The purpose of presenting this case is to highlight the 
distinctive manifestation of mucopolysaccharidosis type II (Hunter syndrome).
Case presentation: A 10-year-old East Asian boy presented with abdominal distension of five years' duration and 
complained of shortness of breath on and off for the same period. On examination his head was large and his head 
circumference was 54.5 cm. His neck was short, he had coarse facial features, a depressed nasal bridge and small 
stubby fingers with flexion of distal interphalangeal joints, and a low arched palate was observed. There was mild 
mental retardation.
Conclusion: Based on clinical findings and radiological features it is possible to diagnose a case of 
mucopolysaccharidosis.
Careful and systemic approach is needed to accurately diagnose the exact type as enzymatic studies are not available 
in most centers.
Introduction
Mucopolysaccharidosis (MPS) is a group of autosomal
recessive metabolic disorders caused by the absence or
malfunctioning of the lysosomal enzymes needed to
break down molecules called glycosaminoglycans
(GAGs). These are long chains of sugar carbohydrates in
each cell that help build bone, cartilage, tendons, corneas,
skin and connective tissues. Glycosaminoglycans (for-
merly called mucopolysaccharides) are also found in the
fluid that lubricates joints. People with MPS either do not
produce enough of one of the 11 enzymes required to
break down these sugar chains into proteins and simpler
molecules, or they produce enzymes that do not work
properly. Over time, these GAGs collect in the cells,
blood and connective tissues. This results in permanent,
progressive cellular damage which affects the appearance,
physical abilities, organ and system functioning and, in
most cases, mental development. Common clinical pre-
sentation includes facial dysmorphism, hepatosplenom-
egaly, joint stiffness and contractures, pulmonary
dysfuction, myocardial enlargement and valvular dys-
function and neurological involvement. As there is no
effective therapy for MPS type II (Hunter syndrome), care
has been predominantly palliative. However, enzyme
replacement therapy (ERT) with recombinant human
iduronate-2-sulfatase has now been introduced. We
report this case of MPS type II because of its rarity and
the atypical features of mild mental retardation with nor-
mal intelligence, acrocephalic head, no corneal clouding
and all other features suggestive of MPS type II. There-
fore, not all MPS necessarily show symptoms of mental
retardation, corneal clouding or atypical features such as
a dolichocephalic head. The purpose of presenting this
case is to highlight the distinctive manifestation of
Hunter syndrome.
Case presentation
A ten-year-old East Asian boy presented to the Pediatric
Out-Patients Department with abdominal distension of
five years' duration and having suffered shortness of
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breath on and off for the same period. Abdominal disten-
sion, without abdominal pain, had been gradual and pro-
gressive since he was five. There was also a history of
joint pain on and off during the past two to three years.
There was no history of constipation, diarrhea, vomiting,
bleeding, jaundice, seizure, weight loss or loss of appetite
or of consciousness. His bladder habit was normal. He
started school at seven years of age and was below aver-
age in his studies.
On examination his head was acrocephalic in shape,
with a circumference of 54.5 cm. He had a depressed
nasal bridge, a short neck, coarse facial features, small
stubby fingers with flexion of the distal interphalangeal
joint, and a low arched palate (Figure 1). Anthropometric
examination showed him to be severely stunted without
wasting. His fundus appeared normal. His abdomen was
soft and slightly distended with a protruding umbilicus.
His liver was 11 cm below the right costal margin in the
mid-clavicular line, with a firm, sharp margin and a
smooth surface with a span of 12 cm. His spleen was 2 cm
below the left costal margin in the mid-clavicular line. His
heart had a grade 2/6 non-radiating systolic murmur in
the mitral area. Suspecting MPS, we performed a skeletal
survey. Anteroposterior and lateral X-rays of the skull
showed an enlarged and J-shaped sella turcica (Figure 2).
The bones of the skull and sutures appeared normal for
his age. Anteroposterior and lateral X-rays of the dor-
solumbar spine showed anterior beaking (Figure 3). Ver-
tebral bodies appeared ovoid due to convexity of the
superior and inferior surfaces. Spinal curvature was nor-
mal and vertebral body height also appeared normal. X-
rays of both hands showed his phalanges and metacarpals
to be widened with proximal tapering of the metacarpals
(Figure 4). The remaining bones and joints under view
appeared normal. An anteroposterior X-ray showed his
ribs as wide with tapered posterior ends (a paddle and/or
spatulated appearance) (Figure 5). No parenchymal
lesions were seen in visualized lung fluids.
Although his radiological features were suggestive of
MPS, without determining the type of MPS, from his his-
tory and clinical examination we have made a diagnosis
of MPS type II (Hunter syndrome). However in our
patient there was atypical presentation such as an acro-
cephalic head, mild mental retardation, and no corneal
clouding, which are important features of MPS type II.
Unfortunately we could not perform any measurement of
GAG, keratan and heparan sulphates, in his urine
because of the lack of test kits. Enzyme assay for idu-
ronate sulfatase is not carried out in our laboratory there-
fore it was not performed either. Our diagnosis of MPS
was confirmed from his history, clinical examination and
skeletal survey.
Figure 1 Child with mucopolysaccharidosis showing an acro-
cephalic head, coarse facial features, a depressed nasal bridge 
and a protuberant abdomen.
Figure 2 Anteroposterior and lateral X-ray of the skull showing a 
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Discussion
In our case all the clinical features such as short stature, a
large head, organomegaly, a depressed nasal bridge, a
short neck, coarse facial features, small stubby fingers,
mild mental retardation with normal intelligence; and
r a d i o l o g i c a l  f e a t u r e s  s u c h  a s  a  J - s h a p e d  s e l l a  t u r c i c a ,
beaking of vertebrae, proximal tapering of metacarpal
bones and tapering of the posterior ends of ribs (paddle
and/or spatulated ribs) as well as his developmental his-
tory were all suggestive of MPS type II.
Mucopolysaccharidosis was first described by Charles
Hunter, a Canadian physician, who in 1917 described a
rare disease found in two brothers [1,2]. Mucopolysac-
charidosis is a group of inherited diseases characterized
by defective lysosomal enzymes responsible for the deg-
radation of mucopolysaccharides, which are major com-
ponents of intercellular connective tissue. This leads to
an accumulation of incompletely degraded mucopolysac-
charides in the lysosomes which affect various body sys-
tems through enzymatic activity [3]. All MPS are
autosomal recessive, except Hunter syndrome which is X-
linked recessive. In affected individuals, undegraded or
partially degraded GAG accumulates within the lyso-
somes and is excreted in excess in the urine. The accumu-
lation of GAG within the lysosomes is responsible for the
clinical manifestation of this disorder [4].
Mucopolysaccharidosis type II or Hunter syndrome is
rare and is caused by a deficiency of iduronate-2-sul-
fatase. Hunter syndrome is one of the most common
MPS with a prevalence of one in 170,000 male live births.
MPS type II is classified into mild (type II, HB) and severe
(type II, A) and this classification is based on the length of
survival and the presence or absence of central nervous
system (CNS) disease. Patients typically appear normal at
birth in both types. In the severe form the clinical fea-
tures appear between two and four years of age while in
the mild form the clinical features appear in the second
decade of life. In the severe form there is severe mental
retardation and loss of skills. Death usually occurs in the
first or second decade of life and the main cause of death
is obstructive airway disease or cardiac failure. In the
milder form there is mild mental retardation but intelli-
gence is normal, stature is near normal, and clinical fea-
Figure 3 Anteroposterior and lateral view of the dorsolumbar 
spine showing beaking of vertebrae.
Figure 4 X-ray of the hands showing phalanges and metacarpals 
are widened with proximal tapering of metacarpals.
Figure 5 Anteroposterior chest X-ray showing paddle and/or 
spatulated ribs.Shah et al. Journal of Medical Case Reports 2010, 4:154
http://www.jmedicalcasereports.com/content/4/1/154
Page 4 of 4
tures are less obvious and progress very slowly. Diagnosis
is usually made in the second decade of life. Death usually
occurs in the fourth decade and the main cause of death
is cardiac failure.
Diagnosis of the disease is usually made by clinical pre-
sentation and skeletal survey. The common clinical pre-
sentations are a large head (dolichocephalic), short
stature, mental retardation, coarse facial features, a pro-
tuberant abdomen, a broad nose with flared nostrils,
large jaws, hypotonia and a large tongue which becomes
apparent between two and four years of age, and these
clinical features were present in our case. Other clinical
features include upper respiratory tract infection, valvu-
lar heart disease leading to right and left ventricular
hypertrophy and heart failure, chronic diarrhea, enlarged
liver and spleen, umbilical as well as inguinal hernia, cor-
neal clouding with poor vision and hearing loss caused by
both connective and sensorineural deficits. A communi-
cating hydrocephalus is a common finding and can lead
to severe manifestation of neurological signs which were
not present in our case.
Analysis of GAGs (heparan and dermatan sulphates) is
a screening test for MPS type II. The presence of excess
heparan and dermatan sulphates in the urine is evidence
of MPS type I, MPS type II or MPS type VII. Confirma-
tory diagnosis is by enzyme assay in leukocytes, fibro-
blasts or dried blood spots and plasma sample, using
substrates specific for 12S. Absent or low 12S activity in
males is diagnostic of Hunter syndrome, provided other
sulfatase deficiency has been ruled out.
Enzyme replacement therapy using idursulfase
(Elaprase), a recombinant human 12S produced in the
human cell line, has been recently approved in the United
States and the European Union for the management of
MPS type II. Weekly intravenous infusion is given over
three hours at a dose of 0.5 mg/kg diluted in saline. Bone
marrow transplantation (BMT) and umbilical cord blood
transplantation (UCBT) are definitive treatments for
MPS. Apart from these, supportive management is very
important. Physical therapy and daily exercise may
improve mobility of joints. Blood transfusion, infection
and nutritional management are also important in the
management of MPS type II. It has been found that fibro-
blast from patients shows metachromatic cytoplasmic
inclusions [5]. A mild form (MPS type IIB) is compatible
with survival into adulthood, and reproduction is known
to have occurred [6]. Six cases of this mild form of Hunter
syndrome have been described, and the patients survived
to the ages of 65 and 87 in two cases. Three of these
affected men had children [7]. The enzyme deficient in
this disorder is iduronate sulfatase, as described by
Neufeld (1987) [8]. Occurrence of Mongolian spots in
seven Japanese infants with Hunter syndrome before and
after hematopoietic stem cell transplantation (HSCT) has
been observed [9].
Conclusion
Mucopolysaccharidosis is a multisystem disorder which
presents with a constellation of clinical findings. Careful
and systemic approach is needed to accurately diagnose
the exact type as enzymatic studies are not available in
most centers.
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